Antibody-Drug-Conjugates: State-of-the-Art Cancer Treatments

E-LEARNING: Antibody-Drug-Conjugates: State-of-the-Art Cancer Treatments

Date: Available in the members area
Start/End: 1,5 hours
Location: virtual


The E-Learning on ADCs in Breast Cancer Treatment hosted by ABCSG-president Prof. Dr. Michael Gnant is a joint project of ABCSG and Daiichi-Sankyo. In this on demand continuing education format with three lectures followed by a panel discussion you will learn about the advancements with next generation ADCs, the successful management of adverse events as well as current standards and future perspectives in HER2-treatment.

Duration of the video approx. 1,5 hours.

The demand-video is now → available in the members area!       

Download program

Online Portal

Access the E-Learning via the ABCSG Members Area (Health Care Professional only). If you are interested and not registered yet, you can register via Otherwise, please log in via

Share on